AbbVie (ABBV) Is Today's Pre-Market Laggard Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified AbbVie ( ABBV) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified AbbVie as such a stock due to the following factors:

  • ABBV has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $660.5 million.
  • ABBV traded 95,169 shares today in the pre-market hours as of 7:41 AM.
  • ABBV is down 4.6% today from Friday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ABBV with the Ticky from Trade-Ideas. See the FREE profile for ABBV NOW at Trade-Ideas

More details on ABBV:

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The stock currently has a dividend yield of 2.8%. ABBV has a PE ratio of 23.0. Currently there are 5 analysts that rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for AbbVie has been 11.7 million shares per day over the past 30 days. AbbVie has a market cap of $94.6 billion and is part of the health care sector and drugs industry. Shares are up 11.8% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst